At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 295 enrolled
Drug / intervention
BMS-986156 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination With Nivolumab (BMS-936558, Anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating BMS-986156 and Nivolumab for Solid Tumors. Completed, enrolled 295 participants across 27 sites in 10 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and tumor-shrinking ability of experimental medication BMS-986156, when given by itself or in combination with nivolumab in patients with solid cancers that are advanced or cancers that have spread.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesAustralia, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, Switzerland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartOct 2015
First PostedNov 2015
Primary CompletionDec 2019
TodayJul 2026
First PostedNov 6, 2015
Enrollment StartOct 14, 2015
Primary CompletionDec 16, 2019
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 10.7 years ago
Interventions
BMS-986156drug
Nivolumabdrug